Guardant Health, Inc. (GH) stock
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$178.80−6.51 (-3.51%)
Close on Oct 30, 2026Market cap $23.99BP/E –Yield –
Earnings
Guardant Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Oct 28, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$335.00M
+44.3% on a year earlier
Non-GAAP net loss per share, Q2 FY2026
-$0.42
-$0.44 a year earlier
Latest guidance
Raised
Jul 30, 2026 · 9 items
Quarterly results
Revenue and earnings per share from each of Guardant Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Oct 28, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026after the close | $335.00M | +44.3% | -$0.90 | -$0.42 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $301.70M | +48.3% | -$0.85 | -$0.45 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 19, 2026after the close | $281.30M | +39.4% | -$1.00 | -$0.50 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025after the close | $265.20M | +38.5% | -$0.74 | -$0.39 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 30, 2025after the close | $232.10M | +31.0% | -$0.80 | -$0.44 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025after the close | $203.50M | +20.8% | -$0.77 | -$0.49 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 20, 2025after the close | $201.80M | +30.1% | -$0.90 | -$0.62 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $191.50M | +33.9% | -$0.88 | -$0.45 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | $177.20M | +29.2% | -$0.84 | -$0.48 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $168.50M | +30.9% | -$0.94 | -$0.46 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024after the close | $155.10M | +22.2% | -$1.58 | -$0.64 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023after the close | $143.00M | +21.8% | -$0.73 | -$0.67 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $137.20M | +25.8% | -$0.67 | -$0.82 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | $128.70M | +33.9% | $1.30 | $1.06 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023after the close | $126.90M | +17.4% | $1.36 | $1.17 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $117.40M | +23.8% | $1.58 | $1.18 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $109.10M | – | -$2.25 | -$1.00 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $96.10M | – | -$1.21 | -$0.91 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022after the close | $108.10M | – | $0.89 | $0.69 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $94.80M | – | -$1.06 | -$0.70 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Guardant Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | FY2026 | $1.34B – $1.36B | $1.30B – $1.32B | Raised | Jul 30, 2026 |
| revenue | FY2026 | $1.25B – $1.28B | – | New | Feb 19, 2026 |
| revenue growth | FY2026 | +36% – +38% | +32% – +34% | Raised | Jul 30, 2026 |
| non-GAAP gross marginnon-GAAP | FY2026 | 64% – 65% | 64% – 65% | Reaffirmed | Jul 30, 2026 |
| non-GAAP gross marginnon-GAAP | FY2026 | 64% – 65% | – | New | Feb 19, 2026 |
| free cash flow burn | FY2026 | $195.00M – $205.00M | $185.00M – $195.00M | Raised | Jul 30, 2026 |
| free cash flow burnnon-GAAP | FY2026 | $185.00M – $195.00M | – | New | Feb 19, 2026 |
| Oncology revenue growth | FY2026 | +30% | +28% – +29% | Raised | Jul 30, 2026 |
| Oncology volume growth | FY2026 | +50% | – | Raised | Jul 30, 2026 |
| Shield volume | FY2026 | 270,000 – 285,000 | 230,000 – 245,000 | Raised | Jul 30, 2026 |
| total non-GAAP operating expensesnon-GAAP | FY2026 | $1.08B – $1.10B | $1.05B – $1.07B | Raised | Jul 30, 2026 |
| total non-GAAP operating expensesnon-GAAP | FY2026 | $1.03B – $1.05B | – | New | Feb 19, 2026 |
Guidance vs results
The last range Guardant Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $965.00M – $970.00M | $982.10MΣ4Q | Above range |
| FY2025 | Revenue growth | +31% | +32.9%Σ4Q | Above range |
Guidance history
Every forecast Guardant Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Jul 30, 2026 | free cash flow burn | FY2026 | $195.00M – $205.00M | Raised |
| Jul 30, 2026 | non-GAAP gross margin | FY2026 | 64% – 65% | Reaffirmed |
| Jul 30, 2026 | Shield volume | FY2026 | 270,000 – 285,000 | Raised |
| Jul 30, 2026 | Oncology revenue growth | FY2026 | +30% | Raised |
| Jul 30, 2026 | Oncology volume growth | FY2026 | +50% | Raised |
| Jul 30, 2026 | total non-GAAP operating expenses | FY2026 | $1.08B – $1.10B | Raised |
| Jul 30, 2026 | revenue growth | FY2026 | +36% – +38% | Raised |
| Jul 30, 2026 | revenue | FY2026 | $1.34B – $1.36B | Raised |
| Jul 30, 2026 | Screening revenue | FY2026 | $218.00M – $230.00M | Lowered |
| May 7, 2026 | free cash flow burn | FY2026 | $185.00M – $195.00M | New |
| May 7, 2026 | non-GAAP gross margin | FY2026 | 64% – 65% | New |
| May 7, 2026 | Shield volume | FY2026 | 230,000 – 245,000 | New |
| May 7, 2026 | Oncology revenue growth | FY2026 | +28% – +29% | New |
| May 7, 2026 | total non-GAAP operating expenses | FY2026 | $1.05B – $1.07B | New |
| May 7, 2026 | growth | FY2026 | +32% – +34% | New |
| May 7, 2026 | full year 2026 revenue | FY2026 | $1.30B – $1.32B | New |
| May 7, 2026 | Screening revenue | FY2026 | $186.00M – $198.00M | Lowered |
| Feb 19, 2026 | free cash flow burn | FY2026 | $185.00M – $195.00M | New |
| Feb 19, 2026 | non-GAAP gross margin | FY2026 | 64% – 65% | New |
| Feb 19, 2026 | total non-GAAP operating expenses | FY2026 | $1.03B – $1.05B | New |
| Feb 19, 2026 | revenue | FY2026 | $1.25B – $1.28B | New |
| Oct 29, 2025 | free cash flow burn | FY2025 | $225.00M – $235.00M | Reaffirmed |
| Oct 29, 2025 | non-GAAP gross margin | FY2025 | 64% – 65% | Raised |
| Oct 29, 2025 | Shield volume | FY2025 | 80,000 – 82,000 | New |
| Oct 29, 2025 | Oncology revenue | FY2025 | +25% | New |
| Oct 29, 2025 | Screening revenue | FY2025 | $71.00M – $73.00M | New |
| Oct 29, 2025 | total non-GAAP operating expenses | FY2025 | $865.00M – $875.00M | Raised |
| Oct 29, 2025 | growth | FY2025 | +31% | Raised |
| Oct 29, 2025 | revenue | FY2025 | $965.00M – $970.00M | Raised |
| Jul 30, 2025 | free cash flow burn | FY2025 | $225.00M – $235.00M | New |
| Jul 30, 2025 | non-GAAP gross margin | FY2025 | 63% – 64% | New |
| Jul 30, 2025 | total non-GAAP operating expenses | FY2025 | $840.00M – $850.00M | New |
| Jul 30, 2025 | revenue growth | FY2025 | +24% – +25% | New |
| Jul 30, 2025 | Oncology revenue | FY2025 | +20% | Lowered |
| Jul 30, 2025 | revenue | FY2025 | $915.00M – $925.00M | New |
| Jul 30, 2025 | Screening revenue | FY2025 | $55.00M – $60.00M | Lowered |
| Apr 30, 2025 | free cash flow burn | FY2025 | -$235.00M – -$225.00M | New |
| Apr 30, 2025 | non-GAAP gross margin | FY2025 | 62% – 63% | Reaffirmed |
| Apr 30, 2025 | total non-GAAP operating expenses | FY2025 | $830.00M – $840.00M | Raised |
| Apr 30, 2025 | revenue growth | FY2025 | +19% – +20% | New |
| Apr 30, 2025 | Oncology revenue growth | FY2025 | +18% | Lowered |
| Apr 30, 2025 | revenue | FY2025 | $880.00M – $890.00M | Raised |
| Apr 30, 2025 | Screening revenue | FY2025 | $40.00M – $45.00M | Lowered |
| Feb 20, 2025 | free cash flow burn | FY2025 | $225.00M – $235.00M | New |
| Feb 20, 2025 | non-GAAP gross margin | FY2025 | 62% – 63% | New |
| Feb 20, 2025 | total non-GAAP operating expenses | FY2025 | $815.00M – $825.00M | New |
| Feb 20, 2025 | revenue | FY2025 | $850.00M – $860.00M | New |
| Nov 6, 2024 | free cash flow | FY2024 | -$275.00M – -$265.00M | New |
| Nov 6, 2024 | non-GAAP gross margin excluding screening | FY2024 | 61% – 63% | Reaffirmed |
| Nov 6, 2024 | total non-GAAP operating expenses | FY2024 | $720.00M – $730.00M | Reaffirmed |
| Nov 6, 2024 | revenue growth | FY2024 | +28% – +29% | New |
| Nov 6, 2024 | revenue | FY2024 | $720.00M – $725.00M | Raised |
| Aug 7, 2024 | free cash flow | FY2024 | -$285.00M – -$275.00M | Reaffirmed |
| Aug 7, 2024 | non-GAAP gross margin excluding screening | FY2024 | 61% – 63% | Reaffirmed |
| Aug 7, 2024 | total non-GAAP operating expenses | FY2024 | $720.00M – $730.00M | Reaffirmed |
| Aug 7, 2024 | revenue excluding screening | FY2024 | $690.00M – $700.00M | Raised |
| May 9, 2024 | free cash flow | FY2024 | -$285.00M – -$275.00M | Raised |
| May 9, 2024 | non-GAAP gross margin excluding screening | FY2024 | 61% – 63% | Raised |
| May 9, 2024 | total non-GAAP operating expenses | FY2024 | $720.00M – $730.00M | Lowered |
| May 9, 2024 | revenue excluding screening | FY2024 | $675.00M – $685.00M | Raised |
| Feb 22, 2024 | free cash flow | FY2024 | -$330.00M – -$320.00M | New |
| Feb 22, 2024 | non-GAAP gross margin excluding screening | FY2024 | 60% – 62% | New |
| Feb 22, 2024 | total non-GAAP operating expenses | FY2024 | $740.00M – $750.00M | New |
| Feb 22, 2024 | revenue excluding screening | FY2024 | $655.00M – $670.00M | New |
| Nov 6, 2023 | free cash flow | FY2023 | -$350.00M | Reaffirmed |
| Nov 6, 2023 | revenue | FY2023 | $553.00M – $556.00M | Raised |
| Aug 3, 2023 | free cash flow | FY2023 | -$350.00M | New |
| Aug 3, 2023 | revenue | FY2023 | $545.00M – $550.00M | New |
| May 9, 2023 | free cash outflow | FY2023 | $350.00M | Reaffirmed |
| May 9, 2023 | revenue | FY2023 | $535.00M – $545.00M | Raised |
| Feb 23, 2023 | free cash outflow | FY2023 | $350.00M | New |
| Feb 23, 2023 | revenue | FY2023 | $525.00M – $540.00M | New |
| Nov 3, 2022 | revenue | FY2022 | $440.00M – $450.00M | Lowered |
| Aug 4, 2022 | revenue | FY2022 | $460.00M – $470.00M | Reaffirmed |
| May 5, 2022 | revenue | FY2022 | $460.00M – $470.00M | Reaffirmed |
| Feb 23, 2022 | revenue | FY2022 | $460.00M – $470.00M | New |
| Nov 4, 2021 | revenue | FY2021 | $360.00M – $370.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Guardant Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- News